Skip to main content
SCNX
NASDAQ Life Sciences

Secures $11M in Highly Restrictive Debt Financing with Extensive Collateral and Punitive Default Terms

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Negative
Importance info
9
Price
$0.401
Mkt Cap
$16.301M
52W Low
$0.238
52W High
$2.6
52W Position info
68% above low
Off High info
85% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

SCNX sits 68% above its 52-week low of $0.238 on light trading volume (0.1× avg).

Summary

Scienture Holdings secured $11.0 million in new debt financing under highly restrictive terms, including extensive collateralization and punitive default provisions, indicating significant financial challenges.


Key Events · Financing and Capital Events · SCNX

  • Secured $11.0 Million in New Debt

    The company entered into a Note Purchase Agreement with Streeterville Capital, LLC, securing $11.0 million in net cash proceeds from two secured promissory notes (A-1 and B Notes).

  • High Interest Rates and Costs

    The A-1 Note has an original principal of $8.42 million with a 9% annual interest rate, including a $400,000 original issue discount and $20,000 in transaction costs. The B Note is for $3.0 million at 5% annual interest.

  • Extensive Collateralization

    The obligations are secured by a broad range of assets, including all company and subsidiary assets, intellectual property, and a pledge of all membership interests in a key subsidiary (SCNX Holdings, LLC).

  • Restrictive Covenants and Aggressive Default Terms

    The agreement includes covenants restricting future financing, subsidiary operations, and granting of security interests. 'Trigger Events' can increase the outstanding balance by 5-15% (up to 25% aggregate), leading to automatic debt acceleration at an 18% default interest rate if not cured.


Analysis · SCNX · Life Sciences

Scienture Holdings, a nano-cap company, has secured $11.0 million in new debt financing through two secured promissory notes. While this provides critical capital for working capital and development, the terms are exceptionally onerous, reflecting significant financial distress. The notes carry high interest rates (9% and 5%), include an original issue discount, and are secured by virtually all company and subsidiary assets, including intellectual property. The agreement features highly restrictive covenants, such as limitations on future financing options and subsidiary operations, and aggressive default triggers. Breaching these covenants can lead to a 'Trigger Effect,' increasing the outstanding balance by 5-15% (up to 25% aggregate) and automatic acceleration of the debt at an 18% default interest rate. This financing provides a short-term lifeline but severely limits the company's financial flexibility and exposes it to substantial risk of further debt escalation or asset forfeiture if it fails to meet the stringent conditions.

How filings like this one have moved

In the 30 days to Oct 2, 2026, 39.9% of the 323 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SCNX was trading at $0.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.3M. The 52-week trading range was $0.24 to $2.60. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SCNX - Latest Insights

SCNX
Oct 02, 2026, 8:05 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.1864
Real-time Price: $0.153 info
Change: Reverse Stock Split info
Market Cap: $6.521M info
SCNX
Sep 30, 2026, 4:05 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.220
Real-time Price: $0.153 info
Change: Reverse Stock Split info
Market Cap: $6.521M info
SCNX
Sep 22, 2026, 8:15 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.3128
Real-time Price: $0.153 info
Change: Reverse Stock Split info
Market Cap: $6.521M info
SCNX
Aug 14, 2026, 8:08 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.5298
Real-time Price: $0.153 info
Change: Reverse Stock Split info
Market Cap: $6.521M info
SCNX
Aug 13, 2026, 4:06 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.450
Real-time Price: $0.153 info
Change: Reverse Stock Split info
Market Cap: $6.521M info